Anti-inflammatory drugs aim to mitigate the chronic neuroinflammation seen in AD by targeting pathways like the NF-κB and NLRP3 inflammasome pathways, which are crucial in mediating inflammatory responses in the brain (73). This evidence concerns the gene NLRP3 and Alzheimer disease.